Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA
Abstract
Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea®). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan. Materials & methods: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted. Results: With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month. Conclusion: Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years.
Supplementary Material
References
1.
Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans. Am. Ophthalmol. Soc. 103, 537–567 (2005).
2.
Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch. Clin. Exp. Ophthalmol. 242(8), 690–698 (2004).
3.
Folk JC, Adelman RA, Flaxel CJ, Hyman L, Pulido JS, Olsen TW. Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern® Guidelines. Ophthalmology 123(1), P152–P181 (2016).
4.
Olsen TW, Adelman RA, Flaxel CJ et al. Idiopathic Macular Hole Preferred Practice Pattern® Guidelines. American Academy of Opthalmology (2014).
5.
Wolf S, Wolf-Schnurrbusch U. Spectral-domain optical coherence tomography use in macular diseases: a review. Ophthalmologica 224(6), 333–340 (2010).
6.
Duker JS, Kaiser PK, Binder S et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120(12), 2611–2619 (2013).
7.
Dugas B, Ouled-Moussa R, Lafontaine PO et al. Idiopathic epiretinal macular membrane and cataract extraction: combined versus consecutive surgery. Am. J. Ophthalmol. 149(2), 302–306 (2010).
8.
Grosso A, Panico C. Incidence of retinal detachment following 23-gauge vitrectomy in idiopathic epiretinal membrane surgery. Acta Ophthalmol. 89(1), e98 (2011).
9.
Le Rouic JF, Becquet F, Ducournau D. Does 23-gauge sutureless vitrectomy modify the risk of postoperative retinal detachment after macular surgery? A comparison with 20-gauge vitrectomy. Retina 31(5), 902–908 (2011).
10.
Tarantola RM, Tsui JY, Graff JM et al. Intraoperative sclerotomy-related retinal breaks during 23-gauge pars plana vitrectomy. Retina 33(1), 136–142 (2013).
11.
Tosi GM, Esposti P, Romeo N et al. The incidence of rhegmatogenous retinal complications in macular surgery after prophylactic preoperative laser retinopexy: a retrospective study. Medicine 95(14), e3283 (2016).
12.
Thrombogenics NV. Highlights of prescribing information for JETREA® (Accessed 20 June 2016). www.accessdata.fda.gov/drugsatfda_docs/label/2012/125422s000lbl.pdf.
13.
Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS) randomized trial. Ophthalmology 123(10), 2232–2247 (2016).
14.
Thrombogenics NV. Ocriplasmin TG-MV-014 OASIS clinical study report (2015) (Data on file).
15.
Stalmans P, Benz MS, Gandorfer A et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N. Engl. J. Med. 367(7), 606–615 (2012).
16.
Institute for Clinical and Economic Review. Estimating the value of new drugs and devices (Accessed 26 July 2016). http://icer-review.org/wp-content/uploads/2016/02/Slides-on-value-framework-for-website-v4-13-16.pdf.
17.
Martin AB, Hartman M, Benson J, Catlin A. National Health Spending in 2014: faster growth driven by coverage expansion and prescription drug spending. Health Affairs 35(1), 150–160 (2016).
18.
Sullivan SD, Mauskopf JA, Augustovski F et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 17(1), 5–14 (2014).
19.
National Institute for Health and Care Excellence. Ocriplasmin for treating vitreomacular traction – technology appraisal guidance [TA297] (Accessed 29 August 2018). www.nice.org.uk/guidance/ta297.
20.
Meuer SM, Myers CE, Klein BE et al. The epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain optical coherence tomography: the Beaver Dam eye study. Ophthalmology 122(4), 787–795 (2015).
21.
Klein R, Lee KE, Gangnon RE, Klein BE. Incidence of visual impairment over a 20-year period: the Beaver Dam eye study. Ophthalmology 120(6), 1210–1219 (2013).
22.
United States Census Bureau. National population projections: 2014 to 2060 population projections based on census 2010 (Accessed 5 May 2016). www.census.gov/population/projections/data/national/.
23.
Zapata MA, Figueroa MS, Esteban González E et al. Prevalence of vitreoretinal interface abnormalities on spectral-domain OCT in healthy participants over 45 years of age. Ophthalmol. Retina 1(3), 249–254 (2017).
24.
Xu LT, Punjabi OS, Shao J et al. Frequency of vitreomacular interface disease in patients presenting to a tertiary care institution. Ophthalmic Surg. Lasers Imaging Retina 45(6), 517–520 (2014).
25.
Thrombogenics NV. JETREA US ATU Q4 2014 final report (2014) (Data on file).
26.
Bennison C, Stephens S, Lescrauwaet B, Van Hout B, Jackson TL. Cost–effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole. J. Mark. Access Health Policy 4 (2016).
27.
Centers for Medicare and Medicaid Services. Physician fee schedule (Accessed 2 August 2018). www.cms.gov/apps/physician-fee-schedule/.
28.
Centers for Medicare and Medicaid Services. Physician/Supplier Procedure Summary Master File (Accessed 21 August 2018). www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/NonIdentifiableDataFiles/PhysicianSupplierProcedureSummaryMasterFile.html.
29.
Centers for Medicare and Medicaid Services. Outpatient and carrier (Part B) 5% Standard Analytical Files. (2008–2012).
30.
Centers for Medicare and Medicaid Services. Ambulatory Surgical Center (ASC) payment – July 2018 ASC approved HCPCS code and payment rates (Accessed 21 August 2018). www.cms.gov/medicare/medicare-fee-for-service-payment/ascpayment/11_addenda_updates.html.
31.
Centers for Medicare and Medicaid Services. Hospital outpatient PPS – July 2018 addendum B update (Accessed 21 August 2018). www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates-Items/2018-January-Addendum-B.html.
32.
First Coast Service Options. 2018 Medicare part B ASC fee schedule – Puerto Rico, CBSA10380 (Accessed 21 August 2018). https://medicare.fcso.com/data_files/index.asp.
33.
Noridian Healthcare Solutions. ASC payment rates, Santa Cruz County, CBSA42100 (Accessed 21 August 2018). https://med.noridianmedicare.com/web/jeb/fees-news/fee-schedules/asc-fees.
34.
Centers for Medicare and Medicaid Services. 2018 ASP drug pricing files (Accessed 2 August 2018). www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles.html.
35.
Truven Health Analytics. Micromedex 2.0 RED BOOK online (Accessed 21 August 2018). www.micromedexsolutions.com/.
36.
Thrombogenics NV. Physician office: coding and billing For JETREA® (Accessed 2 August 2018). http://jetreacare.com/coding-and-billing-guide/physician-coding-and-billing-guide/.
37.
Centers for Medicare and Medicaid Services. Medicare 2018 costs at a glance (Accessed 29 August 2018). www.medicare.gov/your-medicare-costs/costs-at-a-glance/costs-at-glance.html.
38.
United States Department of Labor, Bureau of Labor Statistics. Consumer price index – all urban consumers (2 August 2018). http://data.bls.gov/cgi-bin/surveymost?cu.
39.
Kaiser PK, Kampik A, Kuppermann BD, Girach A, Rizzo S, Sergott RC. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina 35(6), 1111–1127 (2015).
40.
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–6. Value Health 15(6), 835–842 (2012).
41.
Garcia-Perez L, Abreu-Gonzalez R, Perez-Ramos J, Garcia-Perez S, Serrano-Aguilar P. Review of economic studies and budget impact analysis of ocriplasmin as a treatment of vitreomacular traction. Arch. Soc. Esp. Oftalmol. 91(6), 257–264 (2016).
42.
Chang JS, Smiddy WE. Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes. Ophthalmology 121(9), 1720–1726 (2014).
Information & Authors
Information
Published In
Copyright
© 2018 Yu et al.
History
Received: 2 July 2018
Accepted: 19 September 2018
Published online: 23 October 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0057
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Perry Thompson, Hossein Nazari, Pharmacologic Vitreolysis, Encyclopedia of the Eye, 10.1016/B978-0-443-13820-1.00062-1, (219-224), (2025).
- Arshad M Khanani, Pravin U Dugel, Julia A Haller, Alan L Wagner, Benedicte Lescrauwaet, Ralph Schmidt, Craig Bennison, Cost–effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US, Journal of Comparative Effectiveness Research, 10.2217/cer-2019-0117, 9, 4, (287-305), (2020).